$ILMN

Meister Keith A. sold $85.2M of ILMN (indirect holdings)

Meister Keith A. sold 375,941 indirectly-held shares of ILLUMINA, INC. (ILMN) at an average of $226.74 ($224.72–$231.23, $85.24M total) across 13 trades over 2026-08-25 to 2026-08-27.

Original reporting
SEC EDGAR · Meister Keith A.
Published Aug 27, 2026, 11:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 27, 2026, 11:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ILMN
Bearish
medium confidence
Mentioned
$ILMN
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ILMNBearishLow
01

Why it matters

The sizable director sale could trigger short interest and affect short‑term price dynamics.

02

Market read

Material insider sell by a director is a notable event for traders monitoring ILMN.

03

What to watch

The sale was executed via a 10b5‑1 plan, indicating pre‑planned execution rather than reaction to new information.

Relevance 8/10Novelty 8/10Timing: Filed Aug 27 2026 (Form 4 filing date)

Background

SEC Form 4 filing discloses insider transactions required by the SEC.

Company-level read

Ticker impact

$ILMNBearishMedium confidence
Context

Director Meister Keith A. sold 375,941 shares for $85.2M, reducing his stake to 1,033,910 shares.

Expected impact

Potential short-term downside of 2‑4% as market digests the sale.

Evidence & confidence

The $85M sale by a director is material and likely to be viewed negatively by investors.

Market effects

May weigh on other genomics and diagnostics stocks as investors reassess insider sentiment.

Limited to US biotech sector; no broader regional effect.

Minimal global impact beyond Illumina and its peers.

Counterpoint

Insider may be diversifying portfolio; sale does not necessarily reflect company fundamentals.

Key entities

  • Illumina, Inc.

    US‑listed genomics and diagnostics firm (ticker ILMN).

  • Meister Keith A.

    Director of Illumina who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MRNAMed

Moderna’s Rally May Have Run Out of Steam. Here’s What to Watch Next

Moderna (MRNA) shares fell 20% after leaked trial data for its melanoma vaccine, despite analysts calling results 'strong.' The drop may signal the end of its 700% year-to-date rally. Merck (MRK), partnering on the vaccine, saw minimal impact. Analysts expect Merck to report strong earnings. BioNTech (BNTX) and Illumina (ILMN) are also mentioned.

$ILMNMed

Illumina (ILMN) Shares Skyrocket, What You Need To Know

Illumina (ILMN) shares rose 7.7% after analysts raised price targets, citing expected clinical sales growth and AI applications. The stock closed at $293.84, up 7.6%. Illumina's shares have seen significant volatility, with a 22.4% gain last year on strong earnings. The company has raised its full-year EPS guidance to $4.70. ILMN is up 119% YTD, reaching a 52-week high.

$ILMNHighAI 8/10

Illumina Soars to New High After Index Win

Illumina (ILMN) shares hit a 52-week high after being added to the S&P 500 Equal Weighted Index. The company announced a $300M note offering, strong earnings, and raised full-year guidance. Analysts increased price targets, citing sustainable earnings and clinical sequencing demand. The stock's rise is driven by index inclusion, debt refinancing, and upgraded guidance, with future growth expected from its sequencer business model.

$GRALMed

This test screens for 50 cancers - but whether Medicare and other health insurers will cover it hinges on FDA approval

Grail's Galleri test, which screens for 50 cancers, is under FDA review for approval. A major study failed to prove it detects later-stage cancers, causing skepticism among doctors. Grail's stock dropped 50% on the news but has since rebounded. FDA approval could lead to insurance coverage and impact competitors like Caris Life Sciences and Guardant Health.

$ILMNHighAI 8/10

Illumina Q2FY26 Results: Revenue up 9.5% to $1.16 billion

Illumina reported Q2 2026 revenue of $1.16B, up 9.5% YoY, driven by NovaSeq X demand and clinical consumables growth. Non-GAAP EPS rose 10% to $1.31. The company raised full-year guidance, projecting revenue of $4.60B-$4.64B and EPS of $5.30-$5.40. Management cited strong instrument placements and cost management despite rising expenses. Illumina repurchased 0.9M shares and holds $1.17B in cash. The stock has returned 13.26% annually over 20 years, outperforming the market by 3.84%.